Therefore, miR-223-3p could target and negatively regulate E2F1, and E2F1 up-regulative may abrogate the inhibiting effects of miR-223-3p on lipid accumulation and fibrosis in NAFLD. Here, E2F1 is linked to metabolic dysfunction-associated steatotic liver disease.